T cell immunoreceptor with Ig and ITIM domains (TIGIT)

Where the papers sit

12 papers from the last 6 months study T cell immunoreceptor with Ig and ITIM domains (TIGIT) directly · updated from PubMed 10 Oct 2026

• TIGIT-PVR Cancer Immunity

  TIGIT–PVR signaling is being pursued to reverse immune silence and T-cell exhaustion in cancer. Breast-cancer studies combine TIGIT nanotrapping with STING activation or target the axis with artemisinin liposomes, linking checkpoint biology to metabolism, apoptosis and metastasis. In engineered immunity, TIGIT–CD155 disruption improves adapter CAR-T cytotoxicity, while Hodgkin lymphoma studies assess TIGIT expression as a clinical marker. The recurring question is whether context-specific targeting can produce durable antitumor responses.

  5 papers · 41.7%

• NK-Cell Cancer Immunotherapy

  IL-12 engineering and bacterial training are pushing NK-cell immunotherapy toward stronger and more durable antitumor activity. A TIGIT-targeted IL-12 fusion protein engages NK and CD8+ T cells, while bacterial training seeks long-term NK-cell protection against metastatic recurrence. Both approaches add immune stimulation or memory-like function rather than relying on transient checkpoint release alone. Whether this potency can translate into sustained control without systemic toxicity remains open.

  2 papers · 16.7%

• Others — Cross-Disease Immune Research

  Immune research here ranges from mapping TIGIT-targeted cancer trials to using PD1+ TIGIT+ CD4+ T cells as predictors of anti-TNF response. Other work addresses mezigdomide reversal of T-cell dysfunction in myeloma, vaccine responses in inborn immunity defects, and AI-guided small-molecule discovery. No single disease, mechanism or therapeutic direction links these findings. Their limited common thread is the measurement or manipulation of immune function across cancer, autoimmunity, infection and drug discovery.

  5 papers · 41.7%